Drug name - Letairis
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(5 years from now) | |
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(5 years from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(9 years from now) | |
Drugs and Companies using AMBRISENTAN ingredient
Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil; For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.